US · CSBR
Champions Oncology, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Hackensack, NJ 07601
- Website
- championsoncology.com
Price · as of 2025-04-30
$5.99
Market cap 82.69M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $280.03 | +4,574.96% |
| Intrinsic Value(DCF) | $4.16 | -30.55% |
| Graham-Dodd Method(GD) | $1.97 | -67.08% |
| Graham Formula(GF) | $7.28 | +21.45% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $12.60 | $556.97 | $2,207.54 | $0.00 | $0.00 |
| 2012 | $4.92 | $1,037.70 | $3.10 | $0.00 | $0.00 |
| 2013 | $13.08 | $101.53 | $3.74 | $0.00 | $0.00 |
| 2014 | $12.00 | $57.04 | $5.28 | $0.00 | $0.00 |
| 2015 | $6.36 | $50.76 | $0.00 | $0.00 | $21.23 |
| 2016 | $2.22 | $55.94 | $0.00 | $0.00 | $0.00 |
| 2017 | $2.57 | $87.50 | $0.00 | $0.00 | $0.00 |
| 2018 | $6.25 | $91.01 | $46.90 | $0.00 | $0.00 |
| 2019 | $7.76 | $319.66 | $137.86 | $0.20 | $0.46 |
| 2020 | $9.77 | $184.34 | $265.85 | $0.00 | $0.00 |
| 2021 | $9.65 | $221.69 | $272.02 | $0.68 | $0.96 |
| 2022 | $7.90 | $556.94 | $215.28 | $0.87 | $1.12 |
| 2023 | $6.44 | $165.74 | $50.47 | $0.00 | $0.00 |
| 2024 | $5.05 | $306.70 | $0.00 | $0.00 | $0.00 |
| 2025 | $8.10 | $280.03 | $0.47 | $1.97 | $7.28 |
AI valuation
Our deep-learning model estimates Champions Oncology, Inc.'s (CSBR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $280.03
- Current price
- $5.99
- AI upside
- +4,574.96%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4.16
-30.55% upside
Graham-Dodd
$1.97
-67.08% upside
Graham Formula
$7.28
+21.45% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CSBR | Champions Oncology, Inc. | $5.99 | 82.69M | +4,575% | -31% | -67% | +21% | 23.54 | 29.33 | 1.94 | 17.00 | — | 32.19 | 47.27% | 8.51% | 8.26% | 503.05% | 322.96% | 16.08% | 1.62 | 179.48 | 0.94 | 0.88 | -0.58 | -16111.00% | 1354.00% | -20034.00% | 6.32% | 0.31 | 466.31% | 0.00% | 0.00% | 7.68% | 22.07 | 15.29 | 1.88 | 1.07 |
| ARTV | Artiva Biotherapeutics, I… | $5.82 | 142.85M | +335% | -18% | — | +3,479% | -2.00 | 0.70 | 520.26 | 0.62 | -0.59 | 0.70 | 100.00% | -26805.58% | -23303.98% | -530.93% | 65.16% | -41.55% | 0.08 | — | 15.39 | 15.15 | 0.40 | 33697.00% | -9925.00% | 984.00% | -42.63% | -4.49 | 53.92% | 0.00% | 0.00% | 3.20% | 0.60 | 0.73 | -161.31 | 1.72 |
| ATRA | Atara Biotherapeutics, In… | $5.42 | 39.08M | +2,449% | -49% | — | — | -0.60 | -0.53 | 0.40 | -0.70 | — | -0.53 | 83.71% | -64.71% | -66.23% | 86.92% | 88.27% | -62.20% | -0.45 | -18.08 | 0.48 | 0.33 | -0.25 | -8249.00% | 140402.00% | -6449.00% | -133.48% | -0.51 | 72.96% | 0.00% | 0.00% | 25.61% | -0.64 | -0.77 | 0.41 | -28.32 |
| CNTB | Connect Biopharma Holding… | $2.47 | 138.08M | — | — | — | — | -3.00 | 0.51 | 1.80 | 2.14 | — | 0.51 | 100.00% | -86.24% | -60.03% | -16.18% | 242.61% | -13.76% | 0.00 | — | 11.46 | 11.20 | 3.58 | -7407.00% | — | -4948.00% | -51.91% | -2.79 | 263.24% | 0.00% | 0.00% | 0.00% | 2.08 | 1.91 | -1.79 | -1.11 |
| IFRX | InflaRx N.V. | $0.92 | 62.33M | +5,018% | -48% | — | — | -1.32 | 0.99 | 367.43 | -0.95 | — | 0.99 | -1900.76% | -31973.69% | -27784.96% | -56.18% | -78.66% | -46.95% | 0.01 | -2566.39 | 5.06 | 1.30 | 0.39 | 0.00% | 16279.00% | 2826.00% | -79.79% | -3.43 | -72.12% | 0.00% | 0.00% | 9.72% | -0.82 | -0.89 | 261.45 | -5.01 |
| IMA | ImageneBio Inc | $6.72 | 75.14M | +440% | +18% | — | +475% | -16.94 | 6.62 | 238.26 | -20.21 | — | 6.62 | 100.00% | -1057.14% | -1044.80% | -33.30% | -524.86% | -29.52% | 0.06 | — | 11.80 | 11.54 | 0.90 | -3742.00% | -6179.00% | -4261.00% | -5.52% | -4.27 | -652.59% | 0.00% | 0.00% | 0.00% | -19.38 | -15.59 | 204.87 | 28.99 |
| KLRS | Kalaris Therapeutics Inc | $10.46 | 195.63M | — | — | — | — | -0.84 | 0.44 | — | 1.17 | — | 0.44 | 0.00% | — | — | -172.12% | 207.85% | -96.44% | 0.00 | — | 22.63 | 22.58 | 2.01 | -7213.00% | — | 37909.00% | -136.96% | -12.92 | 254.68% | 0.00% | 0.00% | 232.88% | 1.25 | 1.02 | — | -3.17 |
| MGX | Metagenomi, Inc. Common S… | $1.52 | 57.07M | +1,047% | +86% | — | — | -0.99 | 0.33 | 1.48 | 1.50 | -6.69 | 0.33 | 100.00% | -170.00% | -149.26% | -34.69% | -676.50% | -22.64% | 0.19 | — | 6.91 | 6.69 | -0.22 | 1484.00% | 1684.00% | 1083.00% | -144.84% | -2.92 | -913.98% | 0.00% | 0.00% | 0.00% | 1.41 | 1.11 | -2.39 | -0.37 |
| ORMP | Oramed Pharmaceuticals In… | $3.42 | 136.08M | +1,195% | — | — | — | -5.13 | 0.67 | — | 2.94 | — | 0.67 | 0.00% | — | — | -12.29% | -43.99% | -10.14% | 0.00 | -14.98 | 25.19 | 24.97 | 3.63 | -43571.00% | -10000.00% | -2009.00% | -8.62% | -1.48 | -29.02% | 0.00% | 0.00% | 101.31% | 3.42 | 5.19 | — | 5.11 |
| STRO | Sutro Biopharma, Inc. | $20.47 | 174.27M | -71% | -71% | — | +6,969% | -0.51 | 2.58 | 1.86 | 0.99 | -0.76 | 2.58 | 88.37% | -384.34% | -366.62% | -234.19% | 108.03% | -53.02% | 0.52 | -7.67 | 2.60 | 2.47 | 0.93 | 6629.00% | -5964.00% | 6789.00% | -168.89% | -1.45 | 88.18% | 0.00% | 0.00% | 114.12% | 0.75 | 0.92 | -2.88 | -3.86 |
| STTK | Shattuck Labs, Inc. | $3.92 | 187.78M | +1,035% | -87% | — | — | -0.83 | 0.78 | 10.91 | 0.09 | — | 0.78 | 100.00% | -1408.27% | -1318.13% | -67.23% | -568.84% | -60.18% | 0.04 | — | 8.88 | 8.19 | 0.70 | -2732.00% | 24526.00% | -2580.00% | -97.02% | -6.79 | -427.68% | 0.00% | 0.00% | 0.00% | 0.09 | 0.12 | -1.25 | -4.52 |
About Champions Oncology, Inc.
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
- CEO
- Robert Brainin
- Employees
- 210
- Beta
- 0.35
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4.16 ÷ $5.99) − 1 = -30.55% (DCF, example).